FDA recommends lower dose of zolpidem for patient safety
January 11th 2013In a drug safety communication, FDA has recommended that the bedtime dose of zolpidem, for the treatment of insomnia, be lowered because new data show that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving.
FDA approval addresses noninfectious diarrhea in HIV/AIDS patients
January 11th 2013FDA’s recent approval of crofelemer (Fulyzaq, Salix Pharmaceuticals, under license from Napo Pharmaceuticals), 125-mg delayed-release tablets, the first anti-diarrheal drug for HIV/AIDS patients taking antiretroviral therapy (ART), is a significant step forward in addressing the unmet medical need of people with HIV/AIDS on ART who experience noninfectious diarrhea, which often can lead to reduced treatment compliance.
FDA issues guidance on development of abuse-deterrent opioid formulations
January 10th 2013FDA issued a draft guidance on Jan. 9 to help industry in the development of opioid drug formulations with abuse-deterrent properties, saying it considers development of these products a high public health priority.
Color of generic drugs may affect medication adherence
January 10th 2013Changes in tablet color significantly increase the odds that patients will stop taking their medications, according to a study published online first Dec. 31, 2012, in JAMA Internal Medicine (formerly known as the Archives of Internal Medicine).
Vitamin D deficiency linked to autism
January 3rd 2013Vitamin D deficiency may increase risk for developing autism, a researcher suggests.William Grant, Ph.D., Sunlight, Nutrition, and Health Research Center, San Francisco, Calif., and John Cannell, M.D., Vitamin D Council, San Luis Obispo, Calif., found that children ages 6 to 17 years old who lived in states with lower solar UVB doses during the summer and fall were more likely to be diagnosed with autism than those children who lived in states with higher solar UVB doses.
Medical therapy for PVI reduces repeat procedures
January 3rd 2013The use of aspirin, statins and lifestyle changes prior to elective peripheral vascular intervention for peripheral arterial disease (PAD) may reduce the risk for repeat procedures within six months, according to researchers. However, about half of patients failed to receive this therapy, the researchers found.
New drug approval for adults with CML, Ph+ ALL
December 18th 2012Following priority review, FDA approved ponatinib (Iclusig , ARIAD Pharmaceuticals) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.
Survey: Community pharmacists seldom counsel mentally ill patients
December 17th 2012About 75% of patients with mental illness and their caretakers reported that community pharmacists "seldom or never" assisted them with safety or effectiveness monitoring assistance, according to a National Alliance on Mental Illness (NAMI) online survey.
Court rules California Medi-Cal rates can be cut
December 17th 2012The Ninth U.S. Circuit Court of Appeals has ruled that California has the right to cut reimbursement rates made to Medi-Cal providers-including pharmacies-by 10%, which overturns a lower-court ruling that blocked the rate cuts, according to a recentreport from the Associated Press.